Kicking KRAS to tackle lung cancer

KRAS is one of the most commonly mutated oncogenes in lung cancer but has long been considered undruggable. With the recent FDA approval of sotorasib, supported by positive phase II trial data now published in The New England Journal of Medicine, this is no longer the case.

Detalles Bibliográficos
Autor principal: Abbott, Ben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053182/
https://www.ncbi.nlm.nih.gov/pubmed/35602221
http://dx.doi.org/10.1038/s43856-021-00017-z
_version_ 1784696942749548544
author Abbott, Ben
author_facet Abbott, Ben
author_sort Abbott, Ben
collection PubMed
description KRAS is one of the most commonly mutated oncogenes in lung cancer but has long been considered undruggable. With the recent FDA approval of sotorasib, supported by positive phase II trial data now published in The New England Journal of Medicine, this is no longer the case.
format Online
Article
Text
id pubmed-9053182
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-90531822022-05-20 Kicking KRAS to tackle lung cancer Abbott, Ben Commun Med (Lond) Research Highlight KRAS is one of the most commonly mutated oncogenes in lung cancer but has long been considered undruggable. With the recent FDA approval of sotorasib, supported by positive phase II trial data now published in The New England Journal of Medicine, this is no longer the case. Nature Publishing Group UK 2021-07-23 /pmc/articles/PMC9053182/ /pubmed/35602221 http://dx.doi.org/10.1038/s43856-021-00017-z Text en © Springer Nature Limited 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Highlight
Abbott, Ben
Kicking KRAS to tackle lung cancer
title Kicking KRAS to tackle lung cancer
title_full Kicking KRAS to tackle lung cancer
title_fullStr Kicking KRAS to tackle lung cancer
title_full_unstemmed Kicking KRAS to tackle lung cancer
title_short Kicking KRAS to tackle lung cancer
title_sort kicking kras to tackle lung cancer
topic Research Highlight
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053182/
https://www.ncbi.nlm.nih.gov/pubmed/35602221
http://dx.doi.org/10.1038/s43856-021-00017-z
work_keys_str_mv AT abbottben kickingkrastotacklelungcancer

Ejemplares similares